BioSpace News Archive

According to Nova One Advisor, the global biomarkers market size was exhibited at USD 81.19 billion in 2023 and is projected to hit around USD 284.76 billion by 2033, growing at a CAGR of 13.37% during the forecast period 2024 to 2033.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today

According to Nova One Advisor, the global clinical trials market size was estimated at USD 81.90 billion in 2023 and it is projected to increase USD 153.59 billion by 2033 with a CAGR of 6.49% from 2024 to 2033.

SK Life Science, Inc. today announced the schedule for two oral and six poster presentations at the American Academy of Neurology (AAN) Annual Meeting taking place April 13–18, 2024, virtually and in-person in Denver, Colorado.

Q Bio Inc. announced the launch of Tensor Field Mapping, a new technology for Magnetic Resonance Imaging that provides detailed insights into the human body that were previously unimaginable.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced).

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.

Bright Peak Therapeutics announced the presentation of new data characterizing the mechanisms of action, and potent preclinical antitumor activity of BPT567, a cis-signaling, PD1-IL18 immunoconjugate, at the American Association for Cancer Research Annual Meeting being held on April 4-10, 2024, in San Diego, CA.

Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, announced the appointment of Lori Kunkel, MD, to its Board of Directors.

Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK) today announced preclinical data demonstrating the therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy.